{"id":"W2168104151","doi":"10.1186/1471-2474-15-452","title":"The 'Switch’ study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug","year":2014,"lang":"en","type":"article","venue":"BMC Musculoskeletal Disorders","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Arthritis Society","funders":"Versus Arthritis; National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Medicine; Abatacept; Rituximab; Adalimumab; Golimumab; Etanercept; Rheumatoid arthritis; Infliximab; Internal medicine; TNF inhibitor; Oncology; Physical therapy; Disease; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01732659,0.008247958,0.01066859,0.001259288,0.00181202,0.003805476,0.003625972,0.007977667,0.05503412],"category_scores_gemma":[0.01670821,0.002491881,0.006380879,0.001176208,0.004499732,0.00403918,0.00200942,0.008017628,0.007518053],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002822699,"about_ca_system_score_gemma":0.006063025,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002020287,"about_ca_topic_score_gemma":0.003619884,"domain_scores_codex":[0.9878242,0.007747899,0.001129485,0.001480195,0.0006837177,0.001134494],"domain_scores_gemma":[0.9932209,0.002182697,0.001644665,0.0007925578,0.0008539635,0.00130516],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9842706,0.002536663,0.0001444858,0.003899446,0.001499671,0.00006376491,0.00007985991,0.0003040128,0.0005575633,0.0004804478,0.002495707,0.003667754],"study_design_scores_gemma":[0.9877771,0.008683415,0.0002596087,0.0002121864,0.0004759875,0.00001421744,0.00002062456,0.0002095797,0.00009064264,0.0003430676,0.001895989,0.00001764614],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.0537714,0.002784144,0.003422572,0.001720495,0.005103991,0.9215705,0.005520894,0.0004678947,0.005638133],"genre_scores_gemma":[0.05379426,0.0009735973,0.005410865,0.002061305,0.0009446144,0.9305202,0.001561867,0.00005344933,0.004679935],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.05503412,"threshold_uncertainty_score":0.1841075,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01112195569043501,"score_gpt":0.2996407440323354,"score_spread":0.2885187883419004,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}